Second, GLP-1 RAs can reduce inflammation in coronary arteries
Quantit
Sabemos que, a mayor obesidad, ms severa es la apnea del sueo y ahora se ha visto que con estos medicamentos se reduce hasta un 50% el ndice de apneas e hipoapneas, llegando, en casos moderados, a que el paciente deje de utilizar la CPAP , con la implicacin que eso tiene en su calidad de vida, explica la mdico internista
The standard injection schedule reaches a target maintenance dose of 2.4 mg after approximately 16 weeks
While statins are sometimes mentioned in this context, significant statin-related liver injury is rare Alcohol consumption : Excessive alcohol intake compounds hepatic stress and should be addressed before starting treatment Metabolic syndrome components : Diabetes, hypertension, and dyslipidaemiawhilst often indications for weight loss therapycan independently affect liver health Genetic factors : Rare genetic variations affecting drug metabolism may predispose certain individuals to adverse hepatic reactions Warning signs of liver problems that patients should recognise include: Persistent nausea or vomiting (beyond the initial adjustment period typical with GLP-1 agonists) Unusual fatigue or weakness Loss of appetite Abdominal pain, particularly in the upper right quadrant (which may also indicate gallbladder problems) Dark urine or pale stools Yellowing of the skin or whites of the eyes (jaundice) Unexplained itching It is important to note that many of these symptoms are non-specific and may have other causes
